Tag Archives: biotechnology law

Mayo v. Prometheus – A European View

Posted on March 29, 2012 by Warren Woessner

A Guest Post from Paul Cole, European Patent Attorney, Lucas & Co; Professor of IP law, Bournemouth University. Is a claim to an assay patent-eligible when all its features are known save for how it should be interpreted? The interpretation … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged biotechnology, biotechnology law, biotechnology news, European patent, Federal Circuit, intellectual property, ip, Mayo v Prometheus, Paul Cole, Supreme Court, Warren Woessner | 3 Comments

Legal Challenge To “ObamaCare” Threatens Generic Biologicals

Posted on March 29, 2012 by Warren Woessner

What should not be lost on pharma/biotech patent attorneys or their clients, amidst all the attention given to the Supreme Court’s review of the “Patient Protection and Affordable Health Care Act” – public law 111-48, is that it contains the … Continue reading →

Posted in Follow-On Biologics | Tagged biotechnology law, FDA, Hatch-Waxman, Supreme Court, Warren Woessner | 1 Comment

“Handbook of Quality Procedures Before the EPO”

Posted on March 26, 2012 by Warren Woessner

The ECP, epi and Business Europe have collaborated to produce a downloadable, fifty page guide to practice before the EPO. While not binding on Examiners, it was issued under the authority of the EPO and is a sort of mini-MPEP, … Continue reading →

Posted in EP and UK Practice | Tagged biotechnology law, epi, EPO, European patent, intellectual property, ip, Patent Law, patents, Warren Woessner | Leave a comment

Indian Patent Office Grants Compulsory License To Bayer Drug

Posted on March 21, 2012 by Warren Woessner

Finding that Bayer had failed the requirement to “work” the invention in India, e.g., manufacture and sell at a reasonable price, the Indian Patent Office granted Natco Pharma, an Indian company, a “compulsory license” to make, use and sell a … Continue reading →